Pfizer has completed its acquisition of Hospira, Inc. on September 03, 2015, creating a leading Global Established Pharmaceutical (GEP) Business. Hospira is the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.